Allist's lung cancer drug misses endpoint in global phase 3 trial

Allist Pharmaceuticals and Nasdaq-listed partner ArriVent Biopharma said furmonertinib missed the primary endpoint in FURVENT, a global phase 3 trial of first-line treatment for EGFR exon 20 insertion mutation (exon20ins) non-small cell lung cancer (NSCLC).

The failure hits both the science and the balance sheet. It undercuts the out-licensing case that has driven sentiment around the Chinese biotech, and it lands on accounts that had booked a large paper gain on Allist's stake in its US partner.

Allist, a Shanghai-based oncology developer listed on the STAR Market (688578), disclosed in its 2026 interim report that its holding in ArriVent was carried at about 302 million yuan (about $43 million) as of June 30, up 67.31% from the end of last year, according to corporate records database Tianyancha. The company attributed the increase to ArriVent's rising share price.

That gain was effectively Wall Street pricing in a successful furmonertinib launch. ArriVent's main asset — and its core pitch to Nasdaq investors — is the ex-China rights to furmonertinib, which it licensed from Allist. Its market value rested largely on whether the drug could clear the FDA bar for first-line use.

A paper gain that can reverse

The structure ties a clinical trial's outcome to a partner's share price. When the data fail, the same mechanism works in reverse.

ArriVent's stock is set to fall sharply, which means the tens of millions of yuan in fair-value gains Allist booked earlier could be erased in its third-quarter and annual reports, and may turn into a loss that weighs on net profit.

Why FURVENT was hard to win

EGFR exon 20 insertion mutations have long been one of the toughest targets in NSCLC. The binding pocket is narrow, so a drug must be highly selective to avoid wild-type toxicity, and single agents face rapid resistance in a heterogeneous tumour environment.

FURVENT was designed as a head-to-head test against platinum-based chemotherapy plus pemetrexed. Without a bispecific such as Johnson & Johnson's amivantamab (Rybrevant) or an antibody-drug conjugate (ADC) in combination, a single oral TKI achieving a statistically significant progression-free survival benefit in the first line was always going to be a stretch.

The miss closes the fast path for furmonertinib as an oral monotherapy into first-line Western treatment guidelines. Domestically, Allist has already built a cash-generating franchise on the classic mutations (19 deletion and L858R), with reimbursement coverage and several billion yuan in annual sales. But for investors, the overseas setback removes the main source of premium that would have marked its shift from a China-focused drugmaker to a global one.

The reverse pipeline deal

In August, Allist went the other way, taking an exclusive Greater China licence to ArriVent's ADC candidate AST12608, according to company filings and Tianyancha records.

The move reflects the defensive anxiety of a Chinese biotech dependent on one product. Furmonertinib generates the bulk of Allist's revenue, leaving it exposed to a single asset and a single target. By bringing in a next-generation ADC from the same partner, Allist is trying to build a second growth driver before a patent cliff or further overseas setbacks, and to keep its oncology sales force occupied.

That two-way bundling now casts a shadow. If ArriVent runs into a liquidity squeeze and shrinking market value after the trial failure, its ability to fund the ADC programme and secure supply will come under strain.

The 302 million yuan on Allist's books shows how fragile the cross-border model can be. Missing an endpoint is a normal cost of drug development, but tying a company's valuation to a partner's share price invites volatility well beyond the industry norm. Allist has its domestic sales base. Whether management can reopen an overseas path through PACC new-mutation indications or combination therapy is the question it now has to answer.